Aditxt And Evofem Amend Merger Agreement, Aiming For September 30 Closure; Evofem Acquires FDA-Approved SOLOSEC

Author: Benzinga Newsdesk | July 17, 2024 06:36am

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt's common stock as the consideration for Evofem's common stock in the merger and additional changes relating to it. Aditxt and Evofem are diligently working to close the contemplated transaction in the second half of 2024.

The closing of the transaction between Aditxt and Evofem remains subject to the successful satisfaction of a number of closing conditions, including, but not limited to, Aditxt securing sufficient financing to fund its obligations at closing. 

Posted In: ADTX EVFM